Trial Profile
A Phase II Trial of CCI-779 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 19 Sep 2005 New trial record.